Holen Sie sich die Stockscreener-App
3.75
3.59%
0.13
Handel nachbörslich:
3.77
0.02
+0.53%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt IOVA?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$3.62
Offen:
$3.73
24-Stunden-Volumen:
10.56M
Relative Volume:
0.70
Marktkapitalisierung:
$1.54B
Einnahmen:
$263.44M
Nettoeinkommen (Verlust:
$-390.98M
KGV:
-3.3452
EPS:
-1.121
Netto-Cashflow:
$-336.24M
1W Leistung:
-0.53%
1M Leistung:
-2.09%
6M Leistung:
+85.64%
1J Leistung:
+7.76%
1-Tages-Spanne:
$3.69
$3.9689
1-Wochen-Bereich:
$3.43
$3.9689
52-Wochen-Spanne:
$1.6385
$5.63
Iovance Biotherapeutics Inc Stock (IOVA) Company Profile
Firmenname
Iovance Biotherapeutics Inc
Sektor
Branche
Telefon
(650) 260-7120
Adresse
825 INDUSTRIAL ROAD, SAN CARLOS
Compare IOVA vs VRTX, REGN, ALNY, ARGX, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IOVA
Iovance Biotherapeutics Inc
|
3.75 | 1.49B | 263.44M | -390.98M | -336.24M | -1.121 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Iovance Biotherapeutics Inc Stock (IOVA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-25 | Hochstufung | Citizens | Mkt Perform → Mkt Outperform |
| 2025-07-15 | Herabstufung | Goldman | Neutral → Sell |
| 2025-05-16 | Herabstufung | UBS | Buy → Neutral |
| 2025-05-12 | Herabstufung | Truist | Buy → Hold |
| 2025-05-09 | Herabstufung | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-07-29 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2023-11-20 | Eingeleitet | Goldman | Buy |
| 2023-09-18 | Bestätigt | Barclays | Overweight |
| 2023-05-30 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-03-27 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2023-01-27 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-12-09 | Herabstufung | Goldman | Buy → Neutral |
| 2022-10-31 | Eingeleitet | Guggenheim | Neutral |
| 2022-08-18 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2022-01-28 | Hochstufung | Stifel | Hold → Buy |
| 2021-12-07 | Fortgesetzt | Cowen | Outperform |
| 2021-06-10 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2021-05-20 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-05-19 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2021-05-19 | Herabstufung | Stifel | Buy → Hold |
| 2021-05-03 | Eingeleitet | Truist | Buy |
| 2021-04-16 | Eingeleitet | Goldman | Buy |
| 2021-03-08 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-12-15 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2020-10-06 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-04-22 | Eingeleitet | Mizuho | Buy |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2020-02-26 | Bestätigt | H.C. Wainwright | Buy |
| 2020-02-26 | Bestätigt | Oppenheimer | Outperform |
| 2019-12-18 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2019-10-01 | Eingeleitet | Stifel | Buy |
| 2019-04-29 | Eingeleitet | Piper Jaffray | Overweight |
| 2019-02-28 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-02-07 | Eingeleitet | Robert W. Baird | Outperform |
| 2018-12-31 | Fortgesetzt | B. Riley FBR | Buy |
| 2018-07-06 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-04-10 | Hochstufung | B. Riley FBR, Inc. | Neutral → Buy |
| 2018-03-13 | Bestätigt | B. Riley FBR, Inc. | Neutral |
| 2018-02-23 | Herabstufung | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-01-25 | Bestätigt | H.C. Wainwright | Buy |
| 2017-11-01 | Bestätigt | B. Riley FBR, Inc. | Buy |
Alle ansehen
Iovance Biotherapeutics Inc Aktie (IOVA) Neueste Nachrichten
Iovance Biotherapeutics Announces Upcoming Board Member Retirement - The Globe and Mail
A Look At Iovance Biotherapeutics (IOVA) Valuation After Pipeline And Regulatory Updates At Barclays Healthcare Conference - Sahm
Iovance Biotherapeutics board member Wendy Yarno to retire after current term - Investing.com
Form 8K Iovance Biotherapeutics Inc For: 20 March - Investing.com
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
New Iovance hire gets stock options priced at $3.87 a share - Stock Titan
Board member Wendy Yarno to retire from Iovance (NASDAQ: IOVA) after 2026 meeting - Stock Titan
Analyst Sentiment Remains Strong on Iovance Biotherapeutics (IOVA) Amid U.S. Rollout of Melanoma Drug, Amtagvi - Yahoo Finance
IOVA Stock Price, Quote & Chart | IOVANCE BIOTHERAPEUTICS INC (NASDAQ:IOVA) - ChartMill
Iovance Biotherapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - 富途牛牛
Zacks Research Issues Optimistic Forecast for IOVA Earnings - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Encourages Iovance Biotherapeu - The National Law Review
IOVANCE BIOTHERAPEUTICS INC (1IOVA.MI) latest press releases and corporate news - Yahoo Finance Singapore
Long Focus Capital Management LLC Reduces Stock Position in Iovance Biotherapeutics, Inc. $IOVA - MarketBeat
Iovance Biotherapeutics (IOVA) Is Down 25.3% After Strong Early TIL Sarcoma Data Spurs Registrational TrialWhat's Changed - Sahm
Invenomic Capital Management LP Buys 2,246,945 Shares of Iovance Biotherapeutics, Inc. $IOVA - MarketBeat
Iovance Presents Five-Year Amtagvi Data at ASCO for Advanced Melanoma - MSN
IOVA Stock Quote Price and Forecast - CNN
Iovance Biotherapeutics: The High‑Risk Cancer Stock I Think Could Change a Portfolio by 2036 - AOL.com
Iovance Biotherapeutics (IOVA) Announces Positive Early Data for Lifileucel TIL Therapy in Advanced Sarcomas - Yahoo Finance
Iovance Biotherapeutics (IOVA) announces positive early data for lifileucel TIL therapy in advanced sarcomas - MSN
Iovance Biotherapeutics Takes Steps Amidst Market Dynamics - timothysykes.com
What's going on with Iovance Biotherapeutics stock on Friday? - MSN
Why 2 Small Biotechs May Hold the Key to New Cancer Treatments - MarketBeat
Iovance Biotherapeutics’ Latest Moves Shape Market Outlook - StocksToTrade
Iovance Biotherapeutics Faces Challenging Market Dynamics Amidst Financial Strain - timothysykes.com
Iovance Biotherapeutics Inc (IOVA) Stock Price, Trades & News - GuruFocus
IOVANCE (NASDAQ: IOVA) CFO awarded 132,200 RSUs in equity grant - Stock Titan
235,000 RSUs granted to Iovance (NASDAQ: IOVA) interim CEO Frederick Vogt - Stock Titan
Equity grant: IOVANCE (NASDAQ: IOVA) awards 117,500 RSUs to Chief Regulatory Officer - Stock Titan
Iovance (NASDAQ: IOVA) CMO awarded 58,750 RSUs as equity compensation - Stock Titan
IOVANCE (IOVA) Chief Commercial Officer granted 132,200 restricted stock units - Stock Titan
Iovance (NASDAQ: IOVA) COO awarded 117,500 RSUs over 3 years - Stock Titan
Iovance Biotherapeutics (NASDAQ:IOVA) Stock Price Down 7.5%What's Next? - MarketBeat
Iovance Biotherapeutics at Barclays Conference: Strategic Growth and Challenges By Investing.com - Investing.com Canada
A Look At Iovance Biotherapeutics (IOVA) Valuation After Sharp Recent Share Price Momentum - Sahm
Iovance Biotherapeutics (IOVA) Is Up 42.7% After Positive Lifileucel Sarcoma Data And New Trial Plan - Sahm
Iovance Biotherapeutics stock hits 52-week high at 4.35 USD - Investing.com Nigeria
Iovance Biotherapeutics Shines with TIL Therapy Success and Financial Gain - timothysykes.com
Iovance Sarcoma Trial Data Puts TIL Platform And Stock In Focus - Yahoo Finance
Rhenman & Partners Asset Management AB Has $2.38 Million Stock Position in Iovance Biotherapeutics, Inc. $IOVA - MarketBeat
Iovance (IOVA) Soars 33%, Hits All-Time High - Insider Monkey
Iovance (IOVA) Hits 52-Week High as Analyst Doubles Price Target - Finviz
Iovance (IOVA) hits 52-week high as analyst doubles price target - MSN
Momentum Shift: Is Iovance Biotherapeutics Inc. stock a bargain at current levelsJuly 2025 Breakouts & Free Real-Time Market Sentiment Alerts - Naître et grandir
Iovance Biotherapeutics (IOVA) Stock Rallies on Analyst Upgrades, Amtagvi Momentum - International Business Times Australia
Iovance (NASDAQ: IOVA) CMO reports RSU vesting and tax share withholding - Stock Titan
Iovance (NASDAQ: IOVA) CRO reports RSU vesting and tax-share withholding - Stock Titan
Iovance (NASDAQ: IOVA) COO Bilinsky logs 31,246 RSUs vested and tax withholding shares - Stock Titan
Iovance Biotherapeutics jumps as analysts lift targets and short interest fuels momentum - Quiver Quantitative
Iovance Biotherapeutics Expands Clinical Trials Amid Strategic Upgrades - timothysykes.com
Finanzdaten der Iovance Biotherapeutics Inc-Aktie (IOVA)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):